Analysis of patients with non-Hodgkin's lymphoma resistant to therapy.

概要

論文の詳細を見る
Twenty-one newly-diagnosed cases of non-Hodgkin's lymphoma (NHL) were treated with the same therapeutic protocol in our department between January 1984 and December 1986.One patient had a recurrence, and five died. The following results were obtained.1. With combined radiotherapy, VAPE chemotherapy and OK-432 immunotherapy the mean survival rate and the relapse-free survival rate were 76.2% and 71.4%, respectively.2. Adriamycin is useful for NHL. We conclude that even in the early stage, NHL should be treated with full dose VAPE therapy.3. Surgical therapy is presumably useful for a solitary lesion which resists to all conservative therapies.4. Second line chemotherapy for patients who are resistant to VAPE therapy should be established. MTX, CDDP, BLM and Etoposide have possibilities of usefulness as second line chemotherapy.